Aldose Reductase Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Epalrestat | 82159-09-9 | sc-218319 | 10 mg | $200.00 | 2 | |
Epalrestat is another Aldose Reductase inhibitor used in the treatment of diabetic neuropathy. It works by reducing the conversion of glucose to sorbitol. | ||||||
Alrestatin | 51411-04-2 | sc-201443 sc-201443A | 10 mg 50 mg | $113.00 $510.00 | ||
Alrestatin is an Aldose Reductase inhibitor that has been used in research to study the role of Aldose Reductase in diabetic cataracts. | ||||||
Statil | 72702-95-5 | sc-361367 | 100 mg | $235.00 | 1 | |
Ponalrestat is a potent Aldose Reductase inhibitor that has been evaluated for its therapeutic potential in diabetic neuropathy. | ||||||
2-Chloro-1-(4-fluorobenzyl)benzimidazole | 84946-20-3 | sc-206422 | 1 g | $130.00 | ||
2-Chloro-1-(4-fluorobenzyl)benzimidazole exhibits notable interactions with aldose reductase, primarily through its halogen substituents, which enhance binding affinity. The compound's unique electronic properties facilitate the modulation of enzyme kinetics, potentially altering substrate accessibility. Its rigid benzimidazole framework promotes effective stacking interactions with aromatic residues in the active site, influencing catalytic efficiency. This compound's distinct structural features may also impact conformational dynamics, affecting enzyme regulation. | ||||||
EBPC | 57056-57-2 | sc-203572 sc-203572A | 10 mg 50 mg | $115.00 $485.00 | ||
EBPC demonstrates a unique ability to interact with aldose reductase through its specific functional groups, which create a favorable environment for enzyme-substrate binding. The compound's steric configuration allows for optimal orientation within the active site, enhancing catalytic turnover rates. Additionally, its electron-withdrawing characteristics can influence the enzyme's redox state, potentially altering reaction pathways. The presence of multiple substituents contributes to its distinct conformational flexibility, impacting overall enzyme activity. | ||||||
TCS PIM-1 4a | 438190-29-5 | sc-296450 sc-296450A | 10 mg 50 mg | $64.00 $346.00 | ||
TCS PIM-1 4a exhibits remarkable specificity for aldose reductase, facilitated by its unique structural motifs that stabilize enzyme interactions. Its rigid framework promotes effective substrate alignment, enhancing binding affinity. The compound's ability to modulate the enzyme's conformational dynamics can lead to altered kinetic profiles, influencing reaction rates. Furthermore, its unique electronic properties may affect the enzyme's catalytic mechanism, providing insights into substrate channeling and product formation. | ||||||
Tolrestat | 82964-04-3 | sc-474725 | 10 mg | $250.00 | ||
Tolrestat is another Aldose Reductase inhibitor that has been tested for its effects on diabetic complications. | ||||||
Benfotiamine | 22457-89-2 | sc-204639 sc-204639A | 250 mg 1 g | $52.00 $171.00 | ||
While not a direct Aldose Reductase inhibitor, benfotiamine is a synthetic derivative of thiamine (vitamin B1) that can inhibit the activation of the enzyme and prevent the accumulation of sorbitol. | ||||||